Brief: Processa Pharmaceuticals Announces Positive Efficacy Results From Preliminary Evaluation Of Phase 1B Dose-Escalating Trial With NGC-Cap In Gastrointestinal Cancer

Processa Pharmaceuticals

11/06/2024 13:23

June 11 (Reuters) - Processa Pharmaceuticals Inc
 PCSA.O :
    * PROCESSA PHARMACEUTICALS ANNOUNCES POSITIVE EFFICACY
RESULTS
FROM PRELIMINARY EVALUATION OF PHASE 1B DOSE-ESCALATING TRIAL
WITH NGC-CAP IN GASTROINTESTINAL CANCER
    * PROCESSA PHARMACEUTICALS INC - AT HIGHEST NGC-CAP DOSE,
ALL
THREE EVALUABLE PATIENTS HAD PFS WITH TWO PARTIAL RESPONSES (PR)
AND ONE STABLE DISEASE
    * PROCESSA PHARMACEUTICALS INC - EIGHT OF 12 EVALUABLE
PATIENTS
(66.7%) HAD PROGRESSION-FREE SURVIVAL (PFS) RANGING FROM 5 TO 11
MONTHS
    * PROCESSA PHARMACEUTICALS - PRELIMINARY ANALYSIS OF
EFFICACY DATA
SHOWED EARLY EVIDENCE OF ANTI-TUMOR ACTIVITY OF CAPECITABINE
COMBINED WITH PCS6422

Source text for Eikon:  ID:nGNX10SKmW 
Further company coverage:  PCSA.O 

 ((Reuters.Briefs@thomsonreuters.com;))